nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—Adaptive Immune System—ITGAL—psoriasis	0.000581	0.00147	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	0.000578	0.00146	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—NOS2—psoriasis	0.000577	0.00146	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—psoriasis	0.000575	0.00145	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	0.000573	0.00145	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—VEGFA—psoriasis	0.000568	0.00144	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—TYK2—psoriasis	0.000564	0.00143	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—TYK2—psoriasis	0.000561	0.00142	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-E—psoriasis	0.000561	0.00142	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—TYK2—psoriasis	0.000559	0.00141	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TAGAP—psoriasis	0.000557	0.00141	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—TYK2—psoriasis	0.000556	0.0014	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CAT—psoriasis	0.000555	0.0014	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	0.000551	0.00139	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IFIH1—psoriasis	0.000549	0.00139	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—REL—psoriasis	0.000543	0.00137	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—PPARG—psoriasis	0.000539	0.00136	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	0.000539	0.00136	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—STAT3—psoriasis	0.000535	0.00135	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—psoriasis	0.000533	0.00135	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERAP1—psoriasis	0.000528	0.00133	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—TYK2—psoriasis	0.000523	0.00132	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—TYK2—psoriasis	0.000523	0.00132	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—TYK2—psoriasis	0.000523	0.00132	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HLA-C—psoriasis	0.00052	0.00131	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	0.000519	0.00131	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—TYK2—psoriasis	0.000518	0.00131	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—psoriasis	0.000517	0.00131	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TNFAIP3—psoriasis	0.000514	0.0013	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—TYK2—psoriasis	0.000514	0.0013	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—TYK2—psoriasis	0.000511	0.00129	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—NFKB1—psoriasis	0.00051	0.00129	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—ACE—psoriasis	0.000507	0.00128	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-C—psoriasis	0.0005	0.00126	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—JUN—psoriasis	0.000499	0.00126	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—STAT3—psoriasis	0.000496	0.00125	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—SOCS1—psoriasis	0.000488	0.00123	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—STAT3—psoriasis	0.000485	0.00122	CbGpPWpGaD
Lithium—IMPA2—Metabolism—APOE—psoriasis	0.000484	0.00122	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—TYK2—psoriasis	0.000482	0.00122	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—NFKB1—psoriasis	0.000481	0.00121	CbGpPWpGaD
Lithium—GSK3A—Immune System—ITGAL—psoriasis	0.000477	0.0012	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HCAR2—psoriasis	0.000475	0.0012	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL6—psoriasis	0.000473	0.0012	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	0.000471	0.00119	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—SOCS1—psoriasis	0.000469	0.00118	CbGpPWpGaD
Lithium—GSK3B—Immune System—DDX58—psoriasis	0.000465	0.00117	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	0.000463	0.00117	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—JUN—psoriasis	0.000459	0.00116	CbGpPWpGaD
Lithium—GSK3A—Immune System—REL—psoriasis	0.000446	0.00113	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—STAT3—psoriasis	0.000439	0.00111	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	0.000439	0.00111	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NFKBIA—psoriasis	0.000435	0.0011	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—psoriasis	0.000434	0.0011	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—psoriasis	0.000434	0.0011	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFIH1—psoriasis	0.000433	0.00109	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HLA-E—psoriasis	0.000432	0.00109	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—STAT3—psoriasis	0.000432	0.00109	CbGpPWpGaD
Lithium—IMPA1—Metabolism—APOE—psoriasis	0.000431	0.00109	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—psoriasis	0.000429	0.00108	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	0.000427	0.00108	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—psoriasis	0.000424	0.00107	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	0.000423	0.00107	CbGpPWpGaD
Lithium—IMPA2—Metabolism—PPARG—psoriasis	0.000421	0.00106	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HLA-B—psoriasis	0.000416	0.00105	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CD8A—psoriasis	0.000416	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—IL6—psoriasis	0.000415	0.00105	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-E—psoriasis	0.000415	0.00105	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—psoriasis	0.000412	0.00104	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TAGAP—psoriasis	0.000412	0.00104	CbGpPWpGaD
Lithium—GSK3A—Immune System—HLA-C—psoriasis	0.00041	0.00104	CbGpPWpGaD
Lithium—Vision blurred—Prednisolone—psoriasis	0.000409	0.000677	CcSEcCtD
Lithium—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.000409	0.000677	CcSEcCtD
Lithium—Hyperglycaemia—Prednisone—psoriasis	0.000408	0.000676	CcSEcCtD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	0.000407	0.00103	CbGpPWpGaD
Lithium—Arthralgia—Cyclosporine—psoriasis	0.000406	0.000672	CcSEcCtD
Lithium—GSK3A—Immune System—TNFAIP3—psoriasis	0.000405	0.00102	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	0.000404	0.00102	CbGpPWpGaD
Lithium—Convulsion—Mycophenolate mofetil—psoriasis	0.000403	0.000667	CcSEcCtD
Lithium—Discomfort—Cyclosporine—psoriasis	0.000401	0.000664	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—JUN—psoriasis	0.0004	0.00101	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-B—psoriasis	0.0004	0.00101	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—IL6—psoriasis	0.000397	0.001	CbGpPWpGaD
Lithium—Dry mouth—Cyclosporine—psoriasis	0.000397	0.000657	CcSEcCtD
Lithium—Angioedema—Prednisolone—psoriasis	0.000397	0.000656	CcSEcCtD
Lithium—Feeling abnormal—Mycophenolic acid—psoriasis	0.000396	0.000656	CcSEcCtD
Lithium—Arthralgia—Mycophenolate mofetil—psoriasis	0.000396	0.000656	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—STAT3—psoriasis	0.000395	0.000998	CbGpPWpGaD
Lithium—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.000393	0.000651	CcSEcCtD
Lithium—Diarrhoea—Hydroxyurea—psoriasis	0.000393	0.000651	CcSEcCtD
Lithium—Confusional state—Cyclosporine—psoriasis	0.000392	0.00065	CcSEcCtD
Lithium—Discomfort—Mycophenolate mofetil—psoriasis	0.000391	0.000648	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB4—IL6—psoriasis	0.000391	0.000988	CbGpPWpGaD
Lithium—Dysgeusia—Triamcinolone—psoriasis	0.000391	0.000647	CcSEcCtD
Lithium—Vertigo—Prednisolone—psoriasis	0.00039	0.000645	CcSEcCtD
Lithium—Oedema—Cyclosporine—psoriasis	0.000389	0.000644	CcSEcCtD
Lithium—Syncope—Prednisolone—psoriasis	0.000389	0.000644	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL6—psoriasis	0.000388	0.000981	CbGpPWpGaD
Lithium—Dry mouth—Mycophenolate mofetil—psoriasis	0.000387	0.000641	CcSEcCtD
Lithium—Angioedema—Hydrocortisone—psoriasis	0.000387	0.000641	CcSEcCtD
Lithium—Confusional state—Mycophenolate mofetil—psoriasis	0.000383	0.000634	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—JUN—psoriasis	0.000382	0.000966	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisolone—psoriasis	0.000381	0.000631	CcSEcCtD
Lithium—Vertigo—Hydrocortisone—psoriasis	0.000381	0.00063	CcSEcCtD
Lithium—Abdominal pain—Mycophenolic acid—psoriasis	0.00038	0.00063	CcSEcCtD
Lithium—Body temperature increased—Mycophenolic acid—psoriasis	0.00038	0.00063	CcSEcCtD
Lithium—Syncope—Hydrocortisone—psoriasis	0.00038	0.000629	CcSEcCtD
Lithium—Dizziness—Hydroxyurea—psoriasis	0.00038	0.000629	CcSEcCtD
Lithium—Oedema—Mycophenolate mofetil—psoriasis	0.00038	0.000628	CcSEcCtD
Lithium—GSK3B—B Cell Activation—NFKB1—psoriasis	0.000377	0.000953	CbGpPWpGaD
Lithium—Convulsion—Prednisolone—psoriasis	0.000376	0.000622	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—NFKB1—psoriasis	0.000376	0.000949	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PPARG—psoriasis	0.000375	0.000948	CbGpPWpGaD
Lithium—Shock—Mycophenolate mofetil—psoriasis	0.000374	0.000618	CcSEcCtD
Lithium—GSK3A—Downstream signal transduction—IL6—psoriasis	0.000373	0.000943	CbGpPWpGaD
Lithium—Loss of consciousness—Hydrocortisone—psoriasis	0.000373	0.000617	CcSEcCtD
Lithium—Arrhythmia—Betamethasone—psoriasis	0.000372	0.000615	CcSEcCtD
Lithium—Arrhythmia—Dexamethasone—psoriasis	0.000372	0.000615	CcSEcCtD
Lithium—GSK3A—Signaling by FGFR—IL6—psoriasis	0.000372	0.000939	CbGpPWpGaD
Lithium—Anorexia—Cyclosporine—psoriasis	0.000371	0.000614	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—HLA-A—psoriasis	0.000371	0.000936	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—IL6—psoriasis	0.00037	0.000934	CbGpPWpGaD
Lithium—Bradycardia—Prednisone—psoriasis	0.000369	0.00061	CcSEcCtD
Lithium—GSK3A—Innate Immune System—CRP—psoriasis	0.000368	0.00093	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—IL6—psoriasis	0.000368	0.000929	CbGpPWpGaD
Lithium—Alopecia—Dexamethasone—psoriasis	0.000368	0.000608	CcSEcCtD
Lithium—Alopecia—Betamethasone—psoriasis	0.000368	0.000608	CcSEcCtD
Lithium—Convulsion—Hydrocortisone—psoriasis	0.000367	0.000608	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—STAT3—psoriasis	0.000366	0.000925	CbGpPWpGaD
Lithium—Vomiting—Hydroxyurea—psoriasis	0.000365	0.000605	CcSEcCtD
Lithium—Discomfort—Prednisolone—psoriasis	0.000365	0.000604	CcSEcCtD
Lithium—Angioedema—Triamcinolone—psoriasis	0.000365	0.000604	CcSEcCtD
Lithium—Rash—Hydroxyurea—psoriasis	0.000362	0.000599	CcSEcCtD
Lithium—Anorexia—Mycophenolate mofetil—psoriasis	0.000362	0.000599	CcSEcCtD
Lithium—Dermatitis—Hydroxyurea—psoriasis	0.000362	0.000599	CcSEcCtD
Lithium—GSK3B—Innate Immune System—SOCS1—psoriasis	0.000361	0.000911	CbGpPWpGaD
Lithium—Hallucination—Prednisone—psoriasis	0.00036	0.000597	CcSEcCtD
Lithium—Headache—Hydroxyurea—psoriasis	0.00036	0.000596	CcSEcCtD
Lithium—Vertigo—Triamcinolone—psoriasis	0.000359	0.000593	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—STAT3—psoriasis	0.000358	0.000905	CbGpPWpGaD
Lithium—Syncope—Triamcinolone—psoriasis	0.000358	0.000592	CcSEcCtD
Lithium—Discomfort—Hydrocortisone—psoriasis	0.000357	0.00059	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—TYK2—psoriasis	0.000356	0.0009	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	0.000356	0.000899	CbGpPWpGaD
Lithium—Hypotension—Mycophenolate mofetil—psoriasis	0.000355	0.000587	CcSEcCtD
Lithium—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000355	0.000587	CcSEcCtD
Lithium—Oedema—Prednisolone—psoriasis	0.000354	0.000586	CcSEcCtD
Lithium—GSK3B—Immune System—ITGAL—psoriasis	0.000352	0.00089	CbGpPWpGaD
Lithium—Loss of consciousness—Triamcinolone—psoriasis	0.000351	0.000581	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—VEGFA—psoriasis	0.000349	0.000883	CbGpPWpGaD
Lithium—Shock—Prednisolone—psoriasis	0.000348	0.000577	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—psoriasis	0.000348	0.000577	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—SOCS1—psoriasis	0.000346	0.000875	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—IL6—psoriasis	0.000346	0.000874	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	0.000346	0.000874	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—IL6—psoriasis	0.000346	0.000874	CbGpPWpGaD
Lithium—Somnolence—Cyclosporine—psoriasis	0.000346	0.000573	CcSEcCtD
Lithium—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000346	0.000573	CcSEcCtD
Lithium—Oedema—Hydrocortisone—psoriasis	0.000346	0.000573	CcSEcCtD
Lithium—Convulsion—Triamcinolone—psoriasis	0.000346	0.000572	CcSEcCtD
Lithium—Asthenia—Mycophenolic acid—psoriasis	0.000345	0.000571	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—IL6—psoriasis	0.000343	0.000867	CbGpPWpGaD
Lithium—Dyspepsia—Cyclosporine—psoriasis	0.000343	0.000567	CcSEcCtD
Lithium—Nausea—Hydroxyurea—psoriasis	0.000341	0.000565	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-E—psoriasis	0.00034	0.00086	CbGpPWpGaD
Lithium—Shock—Hydrocortisone—psoriasis	0.00034	0.000563	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR in Cancer—IL6—psoriasis	0.00034	0.000859	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HLA-DRB1—psoriasis	0.000339	0.000855	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—IL6—psoriasis	0.000338	0.000855	CbGpPWpGaD
Lithium—Decreased appetite—Cyclosporine—psoriasis	0.000338	0.00056	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—STAT3—psoriasis	0.000338	0.000853	CbGpPWpGaD
Lithium—Somnolence—Mycophenolate mofetil—psoriasis	0.000338	0.000559	CcSEcCtD
Lithium—Drowsiness—Methotrexate—psoriasis	0.000337	0.000558	CcSEcCtD
Lithium—GSK3A—Innate Immune System—NFKBIA—psoriasis	0.000336	0.000848	CbGpPWpGaD
Lithium—Discomfort—Triamcinolone—psoriasis	0.000336	0.000556	CcSEcCtD
Lithium—Fatigue—Cyclosporine—psoriasis	0.000336	0.000555	CcSEcCtD
Lithium—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000334	0.000553	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CCL20—psoriasis	0.000334	0.000843	CbGpPWpGaD
Lithium—Dry mouth—Triamcinolone—psoriasis	0.000332	0.00055	CcSEcCtD
Lithium—Angioedema—Betamethasone—psoriasis	0.000331	0.000548	CcSEcCtD
Lithium—Angioedema—Dexamethasone—psoriasis	0.000331	0.000548	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—CXCL8—psoriasis	0.000331	0.000835	CbGpPWpGaD
Lithium—Decreased appetite—Mycophenolate mofetil—psoriasis	0.00033	0.000546	CcSEcCtD
Lithium—Anorexia—Hydrocortisone—psoriasis	0.00033	0.000546	CcSEcCtD
Lithium—GSK3B—Immune System—REL—psoriasis	0.000329	0.000832	CbGpPWpGaD
Lithium—Diarrhoea—Mycophenolic acid—psoriasis	0.000329	0.000545	CcSEcCtD
Lithium—Oedema—Triamcinolone—psoriasis	0.000326	0.000539	CcSEcCtD
Lithium—Vertigo—Dexamethasone—psoriasis	0.000325	0.000538	CcSEcCtD
Lithium—Vertigo—Betamethasone—psoriasis	0.000325	0.000538	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—ICAM1—psoriasis	0.000325	0.000821	CbGpPWpGaD
Lithium—Syncope—Betamethasone—psoriasis	0.000325	0.000538	CcSEcCtD
Lithium—Syncope—Dexamethasone—psoriasis	0.000325	0.000538	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	0.000324	0.000819	CbGpPWpGaD
Lithium—Arrhythmia—Prednisone—psoriasis	0.000324	0.000536	CcSEcCtD
Lithium—Hypotension—Hydrocortisone—psoriasis	0.000323	0.000535	CcSEcCtD
Lithium—GSK3B—Axon guidance—TYK2—psoriasis	0.000322	0.000814	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NFKBIA—psoriasis	0.000322	0.000814	CbGpPWpGaD
Lithium—Feeling abnormal—Cyclosporine—psoriasis	0.000321	0.000531	CcSEcCtD
Lithium—Shock—Triamcinolone—psoriasis	0.00032	0.00053	CcSEcCtD
Lithium—Alopecia—Prednisone—psoriasis	0.00032	0.00053	CcSEcCtD
Lithium—GSK3B—Immune System—IFIH1—psoriasis	0.00032	0.000808	CbGpPWpGaD
Lithium—Gastrointestinal pain—Cyclosporine—psoriasis	0.000318	0.000527	CcSEcCtD
Lithium—Loss of consciousness—Dexamethasone—psoriasis	0.000318	0.000527	CcSEcCtD
Lithium—Loss of consciousness—Betamethasone—psoriasis	0.000318	0.000527	CcSEcCtD
Lithium—Dizziness—Mycophenolic acid—psoriasis	0.000318	0.000527	CcSEcCtD
Lithium—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000315	0.000522	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—LEP—psoriasis	0.000315	0.000795	CbGpPWpGaD
Lithium—Convulsion—Dexamethasone—psoriasis	0.000314	0.000519	CcSEcCtD
Lithium—Convulsion—Betamethasone—psoriasis	0.000314	0.000519	CcSEcCtD
Lithium—Feeling abnormal—Mycophenolate mofetil—psoriasis	0.000313	0.000518	CcSEcCtD
Lithium—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00031	0.000514	CcSEcCtD
Lithium—GSK3B—Innate Immune System—HLA-B—psoriasis	0.000308	0.000777	CbGpPWpGaD
Lithium—Abdominal pain—Cyclosporine—psoriasis	0.000308	0.000509	CcSEcCtD
Lithium—Body temperature increased—Cyclosporine—psoriasis	0.000308	0.000509	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—JUN—psoriasis	0.000307	0.000777	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD8A—psoriasis	0.000307	0.000776	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—IL6—psoriasis	0.000307	0.000775	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	0.000307	0.000774	CbGpPWpGaD
Lithium—Vomiting—Mycophenolic acid—psoriasis	0.000306	0.000506	CcSEcCtD
Lithium—Discomfort—Betamethasone—psoriasis	0.000305	0.000504	CcSEcCtD
Lithium—Discomfort—Dexamethasone—psoriasis	0.000305	0.000504	CcSEcCtD
Lithium—Dyspepsia—Hydrocortisone—psoriasis	0.000304	0.000504	CcSEcCtD
Lithium—Rash—Mycophenolic acid—psoriasis	0.000303	0.000502	CcSEcCtD
Lithium—GSK3B—Immune System—HLA-C—psoriasis	0.000303	0.000766	CbGpPWpGaD
Lithium—Dermatitis—Mycophenolic acid—psoriasis	0.000303	0.000502	CcSEcCtD
Lithium—GSK3B—Developmental Biology—LEP—psoriasis	0.000301	0.000762	CbGpPWpGaD
Lithium—Headache—Mycophenolic acid—psoriasis	0.000301	0.000499	CcSEcCtD
Lithium—Decreased appetite—Hydrocortisone—psoriasis	0.000301	0.000498	CcSEcCtD
Lithium—Abdominal pain—Mycophenolate mofetil—psoriasis	0.0003	0.000497	CcSEcCtD
Lithium—Body temperature increased—Mycophenolate mofetil—psoriasis	0.0003	0.000497	CcSEcCtD
Lithium—GSK3B—Immune System—TNFAIP3—psoriasis	0.000299	0.000756	CbGpPWpGaD
Lithium—Fatigue—Hydrocortisone—psoriasis	0.000298	0.000494	CcSEcCtD
Lithium—Vision blurred—Prednisone—psoriasis	0.000297	0.000492	CcSEcCtD
Lithium—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000297	0.000491	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—NFKB1—psoriasis	0.000296	0.000748	CbGpPWpGaD
Lithium—Oedema—Dexamethasone—psoriasis	0.000296	0.000489	CcSEcCtD
Lithium—Oedema—Betamethasone—psoriasis	0.000296	0.000489	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—HLA-B—psoriasis	0.000296	0.000747	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—IL6—psoriasis	0.000294	0.000742	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisolone—psoriasis	0.000292	0.000483	CcSEcCtD
Lithium—Shock—Betamethasone—psoriasis	0.000291	0.000481	CcSEcCtD
Lithium—Shock—Dexamethasone—psoriasis	0.000291	0.000481	CcSEcCtD
Lithium—Agitation—Prednisone—psoriasis	0.00029	0.00048	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—IL6—psoriasis	0.000289	0.00073	CbGpPWpGaD
Lithium—Angioedema—Prednisone—psoriasis	0.000288	0.000477	CcSEcCtD
Lithium—Dyspepsia—Triamcinolone—psoriasis	0.000287	0.000475	CcSEcCtD
Lithium—Nausea—Mycophenolic acid—psoriasis	0.000286	0.000473	CcSEcCtD
Lithium—Feeling abnormal—Hydrocortisone—psoriasis	0.000285	0.000472	CcSEcCtD
Lithium—GSK3A—Immune System—SOCS1—psoriasis	0.000284	0.000718	CbGpPWpGaD
Lithium—Vertigo—Prednisone—psoriasis	0.000283	0.000469	CcSEcCtD
Lithium—Gastrointestinal pain—Hydrocortisone—psoriasis	0.000283	0.000468	CcSEcCtD
Lithium—Syncope—Prednisone—psoriasis	0.000283	0.000468	CcSEcCtD
Lithium—Tinnitus—Methotrexate—psoriasis	0.000282	0.000467	CcSEcCtD
Lithium—Anorexia—Dexamethasone—psoriasis	0.000282	0.000466	CcSEcCtD
Lithium—Anorexia—Betamethasone—psoriasis	0.000282	0.000466	CcSEcCtD
Lithium—Fatigue—Triamcinolone—psoriasis	0.000281	0.000465	CcSEcCtD
Lithium—Asthenia—Cyclosporine—psoriasis	0.000279	0.000462	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NFKB1—psoriasis	0.000278	0.000701	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisone—psoriasis	0.000277	0.000459	CcSEcCtD
Lithium—Hypotension—Betamethasone—psoriasis	0.000276	0.000457	CcSEcCtD
Lithium—Hypotension—Dexamethasone—psoriasis	0.000276	0.000457	CcSEcCtD
Lithium—GSK3B—Downstream signal transduction—IL6—psoriasis	0.000276	0.000697	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TYK2—psoriasis	0.000275	0.000695	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—IL6—psoriasis	0.000275	0.000694	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HLA-A—psoriasis	0.000274	0.000692	CbGpPWpGaD
Lithium—Body temperature increased—Hydrocortisone—psoriasis	0.000273	0.000453	CcSEcCtD
Lithium—Abdominal pain—Hydrocortisone—psoriasis	0.000273	0.000453	CcSEcCtD
Lithium—Convulsion—Prednisone—psoriasis	0.000273	0.000452	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—IL6—psoriasis	0.000273	0.00069	CbGpPWpGaD
Lithium—Asthenia—Mycophenolate mofetil—psoriasis	0.000272	0.000451	CcSEcCtD
Lithium—GSK3B—Innate Immune System—CRP—psoriasis	0.000272	0.000687	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—IL6—psoriasis	0.000272	0.000687	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000269	0.000446	CcSEcCtD
Lithium—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000269	0.000446	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—VEGFA—psoriasis	0.000269	0.000679	CbGpPWpGaD
Lithium—Arthralgia—Prednisone—psoriasis	0.000268	0.000444	CcSEcCtD
Lithium—Feeling abnormal—Triamcinolone—psoriasis	0.000268	0.000444	CcSEcCtD
Lithium—Alopecia—Methotrexate—psoriasis	0.000268	0.000443	CcSEcCtD
Lithium—Diarrhoea—Cyclosporine—psoriasis	0.000266	0.000441	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—STAT3—psoriasis	0.000266	0.000672	CbGpPWpGaD
Lithium—Discomfort—Prednisone—psoriasis	0.000265	0.000439	CcSEcCtD
Lithium—GSK3B—Developmental Biology—PPARG—psoriasis	0.000263	0.000663	CbGpPWpGaD
Lithium—Dyspepsia—Dexamethasone—psoriasis	0.00026	0.000431	CcSEcCtD
Lithium—Dyspepsia—Betamethasone—psoriasis	0.00026	0.000431	CcSEcCtD
Lithium—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00026	0.00043	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—psoriasis	0.000258	0.000427	CcSEcCtD
Lithium—Body temperature increased—Triamcinolone—psoriasis	0.000257	0.000426	CcSEcCtD
Lithium—Dizziness—Cyclosporine—psoriasis	0.000257	0.000426	CcSEcCtD
Lithium—Oedema—Prednisone—psoriasis	0.000257	0.000426	CcSEcCtD
Lithium—Decreased appetite—Dexamethasone—psoriasis	0.000257	0.000425	CcSEcCtD
Lithium—Decreased appetite—Betamethasone—psoriasis	0.000257	0.000425	CcSEcCtD
Lithium—GSK3B—DAP12 interactions—IL6—psoriasis	0.000256	0.000646	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	0.000256	0.000646	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—psoriasis	0.000256	0.000646	CbGpPWpGaD
Lithium—Fatigue—Betamethasone—psoriasis	0.000255	0.000422	CcSEcCtD
Lithium—Fatigue—Dexamethasone—psoriasis	0.000255	0.000422	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—IL6—psoriasis	0.000253	0.00064	CbGpPWpGaD
Lithium—Shock—Prednisone—psoriasis	0.000253	0.000419	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—TP53—psoriasis	0.000252	0.000638	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—psoriasis	0.000252	0.000637	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-E—psoriasis	0.000252	0.000636	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—psoriasis	0.000251	0.000635	CbGpPWpGaD
Lithium—Dizziness—Mycophenolate mofetil—psoriasis	0.000251	0.000416	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—HLA-DRB1—psoriasis	0.00025	0.000632	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—IL6—psoriasis	0.00025	0.000632	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—STAT3—psoriasis	0.000249	0.00063	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CD4—psoriasis	0.000249	0.000628	CbGpPWpGaD
Lithium—Vision blurred—Methotrexate—psoriasis	0.000248	0.000411	CcSEcCtD
Lithium—Asthenia—Hydrocortisone—psoriasis	0.000248	0.000411	CcSEcCtD
Lithium—GSK3B—Innate Immune System—NFKBIA—psoriasis	0.000248	0.000627	CbGpPWpGaD
Lithium—Vomiting—Cyclosporine—psoriasis	0.000247	0.00041	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CCL20—psoriasis	0.000247	0.000623	CbGpPWpGaD
Lithium—Rash—Cyclosporine—psoriasis	0.000245	0.000406	CcSEcCtD
Lithium—Anorexia—Prednisone—psoriasis	0.000245	0.000406	CcSEcCtD
Lithium—Dermatitis—Cyclosporine—psoriasis	0.000245	0.000406	CcSEcCtD
Lithium—Headache—Cyclosporine—psoriasis	0.000244	0.000404	CcSEcCtD
Lithium—Feeling abnormal—Dexamethasone—psoriasis	0.000244	0.000403	CcSEcCtD
Lithium—Feeling abnormal—Betamethasone—psoriasis	0.000244	0.000403	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-B—psoriasis	0.000243	0.000613	CbGpPWpGaD
Lithium—Gastrointestinal pain—Dexamethasone—psoriasis	0.000242	0.0004	CcSEcCtD
Lithium—Gastrointestinal pain—Betamethasone—psoriasis	0.000242	0.0004	CcSEcCtD
Lithium—Vomiting—Mycophenolate mofetil—psoriasis	0.000241	0.0004	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—ICAM1—psoriasis	0.00024	0.000607	CbGpPWpGaD
Lithium—Rash—Mycophenolate mofetil—psoriasis	0.000239	0.000396	CcSEcCtD
Lithium—Dermatitis—Mycophenolate mofetil—psoriasis	0.000239	0.000396	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CD4—psoriasis	0.000239	0.000603	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NFKBIA—psoriasis	0.000238	0.000602	CbGpPWpGaD
Lithium—Headache—Mycophenolate mofetil—psoriasis	0.000238	0.000394	CcSEcCtD
Lithium—Vertigo—Methotrexate—psoriasis	0.000237	0.000392	CcSEcCtD
Lithium—Diarrhoea—Hydrocortisone—psoriasis	0.000237	0.000392	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—IL6—psoriasis	0.000236	0.000596	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Prednisone—psoriasis	0.000234	0.000388	CcSEcCtD
Lithium—Dizziness—Prednisolone—psoriasis	0.000234	0.000388	CcSEcCtD
Lithium—Asthenia—Triamcinolone—psoriasis	0.000234	0.000387	CcSEcCtD
Lithium—Abdominal pain—Dexamethasone—psoriasis	0.000234	0.000387	CcSEcCtD
Lithium—Body temperature increased—Dexamethasone—psoriasis	0.000234	0.000387	CcSEcCtD
Lithium—Body temperature increased—Betamethasone—psoriasis	0.000234	0.000387	CcSEcCtD
Lithium—Abdominal pain—Betamethasone—psoriasis	0.000234	0.000387	CcSEcCtD
Lithium—Nausea—Cyclosporine—psoriasis	0.000231	0.000383	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—IL6—psoriasis	0.000231	0.000584	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TYK2—psoriasis	0.00023	0.000581	CbGpPWpGaD
Lithium—Dizziness—Hydrocortisone—psoriasis	0.000229	0.000379	CcSEcCtD
Lithium—Convulsion—Methotrexate—psoriasis	0.000228	0.000378	CcSEcCtD
Lithium—GSK3B—Axon guidance—VEGFA—psoriasis	0.000228	0.000576	CbGpPWpGaD
Lithium—Dyspepsia—Prednisone—psoriasis	0.000227	0.000375	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	0.000227	0.000572	CbGpPWpGaD
Lithium—Nausea—Mycophenolate mofetil—psoriasis	0.000226	0.000373	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-A—psoriasis	0.000225	0.000568	CbGpPWpGaD
Lithium—Arthralgia—Methotrexate—psoriasis	0.000224	0.000371	CcSEcCtD
Lithium—Decreased appetite—Prednisone—psoriasis	0.000224	0.00037	CcSEcCtD
Lithium—Rash—Prednisolone—psoriasis	0.000223	0.00037	CcSEcCtD
Lithium—Dermatitis—Prednisolone—psoriasis	0.000223	0.000369	CcSEcCtD
Lithium—GSK3A—Innate Immune System—JUN—psoriasis	0.000223	0.000562	CbGpPWpGaD
Lithium—Fatigue—Prednisone—psoriasis	0.000222	0.000367	CcSEcCtD
Lithium—Headache—Prednisolone—psoriasis	0.000222	0.000367	CcSEcCtD
Lithium—Discomfort—Methotrexate—psoriasis	0.000222	0.000367	CcSEcCtD
Lithium—Vomiting—Hydrocortisone—psoriasis	0.00022	0.000364	CcSEcCtD
Lithium—Rash—Hydrocortisone—psoriasis	0.000218	0.000361	CcSEcCtD
Lithium—Dermatitis—Hydrocortisone—psoriasis	0.000218	0.000361	CcSEcCtD
Lithium—Confusional state—Methotrexate—psoriasis	0.000217	0.000359	CcSEcCtD
Lithium—Headache—Hydrocortisone—psoriasis	0.000217	0.000359	CcSEcCtD
Lithium—Dizziness—Triamcinolone—psoriasis	0.000215	0.000357	CcSEcCtD
Lithium—GSK3A—Immune System—CRP—psoriasis	0.000214	0.000542	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NFKB1—psoriasis	0.000214	0.000541	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisone—psoriasis	0.000212	0.000351	CcSEcCtD
Lithium—Asthenia—Betamethasone—psoriasis	0.000212	0.000351	CcSEcCtD
Lithium—Asthenia—Dexamethasone—psoriasis	0.000212	0.000351	CcSEcCtD
Lithium—Gastrointestinal pain—Prednisone—psoriasis	0.00021	0.000348	CcSEcCtD
Lithium—Nausea—Prednisolone—psoriasis	0.00021	0.000348	CcSEcCtD
Lithium—GSK3B—Immune System—SOCS1—psoriasis	0.00021	0.000531	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—psoriasis	0.000209	0.000528	CbGpPWpGaD
Lithium—GSK3A—Disease—HLA-A—psoriasis	0.000208	0.000524	CbGpPWpGaD
Lithium—Vomiting—Triamcinolone—psoriasis	0.000207	0.000343	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—NFKB1—psoriasis	0.000206	0.00052	CbGpPWpGaD
Lithium—Nausea—Hydrocortisone—psoriasis	0.000205	0.00034	CcSEcCtD
Lithium—Rash—Triamcinolone—psoriasis	0.000205	0.00034	CcSEcCtD
Lithium—GSK3A—Immune System—HLA-DRB1—psoriasis	0.000205	0.000519	CbGpPWpGaD
Lithium—Dermatitis—Triamcinolone—psoriasis	0.000205	0.00034	CcSEcCtD
Lithium—Anorexia—Methotrexate—psoriasis	0.000205	0.000339	CcSEcCtD
Lithium—Headache—Triamcinolone—psoriasis	0.000204	0.000338	CcSEcCtD
Lithium—Body temperature increased—Prednisone—psoriasis	0.000203	0.000337	CcSEcCtD
Lithium—Abdominal pain—Prednisone—psoriasis	0.000203	0.000337	CcSEcCtD
Lithium—GSK3B—Innate Immune System—TYK2—psoriasis	0.000203	0.000513	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—psoriasis	0.000203	0.000513	CbGpPWpGaD
Lithium—Diarrhoea—Dexamethasone—psoriasis	0.000202	0.000335	CcSEcCtD
Lithium—Diarrhoea—Betamethasone—psoriasis	0.000202	0.000335	CcSEcCtD
Lithium—Hypotension—Methotrexate—psoriasis	0.000201	0.000333	CcSEcCtD
Lithium—GSK3A—Immune System—ICAM1—psoriasis	0.000197	0.000498	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000196	0.000324	CcSEcCtD
Lithium—GSK3A—Immune System—NFKBIA—psoriasis	0.000196	0.000494	CbGpPWpGaD
Lithium—Dizziness—Betamethasone—psoriasis	0.000195	0.000323	CcSEcCtD
Lithium—Dizziness—Dexamethasone—psoriasis	0.000195	0.000323	CcSEcCtD
Lithium—GSK3A—Disease—APOE—psoriasis	0.000194	0.000489	CbGpPWpGaD
Lithium—Nausea—Triamcinolone—psoriasis	0.000193	0.00032	CcSEcCtD
Lithium—Somnolence—Methotrexate—psoriasis	0.000191	0.000317	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—psoriasis	0.000189	0.000313	CcSEcCtD
Lithium—Vomiting—Betamethasone—psoriasis	0.000188	0.000311	CcSEcCtD
Lithium—Vomiting—Dexamethasone—psoriasis	0.000188	0.000311	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—psoriasis	0.000187	0.000309	CcSEcCtD
Lithium—GSK3B—Immune System—CD8A—psoriasis	0.000186	0.000471	CbGpPWpGaD
Lithium—Rash—Dexamethasone—psoriasis	0.000186	0.000308	CcSEcCtD
Lithium—Rash—Betamethasone—psoriasis	0.000186	0.000308	CcSEcCtD
Lithium—Dermatitis—Betamethasone—psoriasis	0.000186	0.000308	CcSEcCtD
Lithium—Dermatitis—Dexamethasone—psoriasis	0.000186	0.000308	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—IL6—psoriasis	0.000186	0.000469	CbGpPWpGaD
Lithium—Fatigue—Methotrexate—psoriasis	0.000185	0.000307	CcSEcCtD
Lithium—Headache—Dexamethasone—psoriasis	0.000185	0.000306	CcSEcCtD
Lithium—Headache—Betamethasone—psoriasis	0.000185	0.000306	CcSEcCtD
Lithium—Asthenia—Prednisone—psoriasis	0.000185	0.000306	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—SOCS1—psoriasis	0.000184	0.000464	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CD4—psoriasis	0.000184	0.000464	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—psoriasis	0.000181	0.000456	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NFKB1—psoriasis	0.000179	0.000453	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-B—psoriasis	0.000179	0.000453	CbGpPWpGaD
Lithium—Feeling abnormal—Methotrexate—psoriasis	0.000177	0.000293	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—CD4—psoriasis	0.000176	0.000446	CbGpPWpGaD
Lithium—Diarrhoea—Prednisone—psoriasis	0.000176	0.000291	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—psoriasis	0.000176	0.000291	CcSEcCtD
Lithium—Nausea—Dexamethasone—psoriasis	0.000176	0.000291	CcSEcCtD
Lithium—Nausea—Betamethasone—psoriasis	0.000176	0.000291	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—IL6—psoriasis	0.000174	0.00044	CbGpPWpGaD
Lithium—Dizziness—Prednisone—psoriasis	0.00017	0.000282	CcSEcCtD
Lithium—Abdominal pain—Methotrexate—psoriasis	0.00017	0.000281	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—psoriasis	0.00017	0.000281	CcSEcCtD
Lithium—GSK3B—Immune System—HLA-A—psoriasis	0.000166	0.00042	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—JUN—psoriasis	0.000164	0.000415	CbGpPWpGaD
Lithium—Vomiting—Prednisone—psoriasis	0.000164	0.000271	CcSEcCtD
Lithium—GSK3B—Developmental Biology—VEGFA—psoriasis	0.000163	0.000411	CbGpPWpGaD
Lithium—Rash—Prednisone—psoriasis	0.000162	0.000269	CcSEcCtD
Lithium—Dermatitis—Prednisone—psoriasis	0.000162	0.000268	CcSEcCtD
Lithium—Headache—Prednisone—psoriasis	0.000161	0.000267	CcSEcCtD
Lithium—GSK3B—Developmental Biology—STAT3—psoriasis	0.000161	0.000407	CbGpPWpGaD
Lithium—GSK3A—Immune System—TYK2—psoriasis	0.00016	0.000405	CbGpPWpGaD
Lithium—GSK3B—Immune System—CRP—psoriasis	0.000158	0.0004	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NFKB1—psoriasis	0.000158	0.0004	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—psoriasis	0.000158	0.000398	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—psoriasis	0.000154	0.000255	CcSEcCtD
Lithium—GSK3B—Disease—HLA-A—psoriasis	0.000153	0.000387	CbGpPWpGaD
Lithium—Nausea—Prednisone—psoriasis	0.000153	0.000253	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—NFKB1—psoriasis	0.000152	0.000384	CbGpPWpGaD
Lithium—GSK3B—Immune System—HLA-DRB1—psoriasis	0.000152	0.000383	CbGpPWpGaD
Lithium—GSK3A—Immune System—IFNG—psoriasis	0.00015	0.000379	CbGpPWpGaD
Lithium—GSK3A—Disease—TYK2—psoriasis	0.000148	0.000374	CbGpPWpGaD
Lithium—Diarrhoea—Methotrexate—psoriasis	0.000147	0.000244	CcSEcCtD
Lithium—GSK3B—Immune System—ICAM1—psoriasis	0.000146	0.000368	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD4—psoriasis	0.000145	0.000366	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKBIA—psoriasis	0.000144	0.000365	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—psoriasis	0.000143	0.000362	CbGpPWpGaD
Lithium—Dizziness—Methotrexate—psoriasis	0.000142	0.000235	CcSEcCtD
Lithium—GSK3B—Developmental Biology—TNF—psoriasis	0.000139	0.000352	CbGpPWpGaD
Lithium—Vomiting—Methotrexate—psoriasis	0.000137	0.000226	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—SOCS1—psoriasis	0.000136	0.000343	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—psoriasis	0.000136	0.000343	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LEP—psoriasis	0.000136	0.000343	CbGpPWpGaD
Lithium—Rash—Methotrexate—psoriasis	0.000136	0.000224	CcSEcCtD
Lithium—Dermatitis—Methotrexate—psoriasis	0.000135	0.000224	CcSEcCtD
Lithium—Headache—Methotrexate—psoriasis	0.000135	0.000223	CcSEcCtD
Lithium—GSK3A—Innate Immune System—IL6—psoriasis	0.000134	0.00034	CbGpPWpGaD
Lithium—GSK3A—Disease—CD4—psoriasis	0.000134	0.000338	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—psoriasis	0.000133	0.000337	CbGpPWpGaD
Lithium—GSK3A—Immune System—JUN—psoriasis	0.00013	0.000327	CbGpPWpGaD
Lithium—Nausea—Methotrexate—psoriasis	0.000128	0.000211	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—NFKBIA—psoriasis	0.000126	0.000319	CbGpPWpGaD
Lithium—GSK3A—Immune System—NFKB1—psoriasis	0.000125	0.000315	CbGpPWpGaD
Lithium—GSK3B—Immune System—TYK2—psoriasis	0.000118	0.000299	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—psoriasis	0.000113	0.000284	CbGpPWpGaD
Lithium—GSK3A—Immune System—STAT3—psoriasis	0.000112	0.000283	CbGpPWpGaD
Lithium—GSK3B—Immune System—IFNG—psoriasis	0.000111	0.00028	CbGpPWpGaD
Lithium—GSK3B—Disease—TYK2—psoriasis	0.000109	0.000276	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD4—psoriasis	0.000107	0.00027	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TYK2—psoriasis	0.000104	0.000262	CbGpPWpGaD
Lithium—GSK3A—Disease—STAT3—psoriasis	0.000104	0.000262	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—psoriasis	0.0001	0.000253	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LEP—psoriasis	0.0001	0.000253	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—psoriasis	9.94e-05	0.000251	CbGpPWpGaD
Lithium—GSK3B—Disease—CD4—psoriasis	9.88e-05	0.00025	CbGpPWpGaD
Lithium—GSK3B—Immune System—JUN—psoriasis	9.58e-05	0.000242	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKBIA—psoriasis	9.34e-05	0.000236	CbGpPWpGaD
Lithium—GSK3B—Immune System—NFKB1—psoriasis	9.22e-05	0.000233	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—psoriasis	9.02e-05	0.000228	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—JUN—psoriasis	8.38e-05	0.000212	CbGpPWpGaD
Lithium—GSK3B—Immune System—STAT3—psoriasis	8.29e-05	0.000209	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NFKB1—psoriasis	8.07e-05	0.000204	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—psoriasis	7.83e-05	0.000198	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TYK2—psoriasis	7.65e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Disease—STAT3—psoriasis	7.65e-05	0.000193	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—psoriasis	7.32e-05	0.000185	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—STAT3—psoriasis	7.25e-05	0.000183	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—psoriasis	7.23e-05	0.000183	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—psoriasis	6.66e-05	0.000168	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—JUN—psoriasis	6.19e-05	0.000156	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NFKB1—psoriasis	5.96e-05	0.000151	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—psoriasis	5.79e-05	0.000146	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—psoriasis	5.53e-05	0.00014	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—psoriasis	5.41e-05	0.000137	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STAT3—psoriasis	5.36e-05	0.000135	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—psoriasis	5.34e-05	0.000135	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—psoriasis	5.06e-05	0.000128	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—psoriasis	4.09e-05	0.000103	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—psoriasis	3.74e-05	9.45e-05	CbGpPWpGaD
